US Compounding Inc has recalled 1,640 units of Neostigmine Methylsulfate PF Injection (5 mg/5 mL) because the syringes were distributed without required labeling. This recall affects single-use syringes intended for hospital or office use only. Without the appropriate label, healthcare providers may not have critical information such as the drug name, concentration, or expiration date, which could lead to medication errors.
A missing label on a medication syringe creates a high risk of administration error, as the user cannot verify the medication type or dosage before use. Using the wrong drug or an incorrect dose can lead to serious patient harm or lack of expected treatment.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.